The ACcomplisH Trial is a global phase 2 clinical trial evaluating the safety and efficacy of TransCon™ CNP, an investigational treatment for children with achondroplasia (ACH) designed to provide continuous exposure to C-type natriuretic peptide (CNP) with once-weekly administration. For a list of participating countries and sites, please see ClinicalTrials.gov.

Pre-pubertal children 2 to 10 years of age with ACH are invited to screen for trial eligibility.

After enrollment into the trial, participants will be randomly assigned to receive TransCon CNP or placebo in a 3:1 ratio. This means for every 4 participants, 3 will be randomly assigned to receive TransCon CNP and 1 will receive placebo. The randomization process to determine which medicine participants will receive is done via a computer system.

• Participants and their doctors will not know who has been assigned to each group
• Participants will receive either TransCon CNP or placebo once a week for 12 months (52 weeks)

Both study medicines are given with a small needle that is inserted under the skin. Participants who successfully complete the ACcomplisH Trial may have the opportunity to receive TransCon CNP in a long-term safety trial.

• No, there is no fee to participate in the ACcomplisH Trial
• Trial-related costs for participants will be covered by Ascendis Pharma for the entire duration of the trial, including:
• TransCon CNP or placebo
• Laboratory tests
• Other trial procedures
• Reimbursement for time and travel expenses may be available in accordance with local regulations